• Aucun résultat trouvé

The European Union Committee of Experts on Rare Diseases (EUCERD): a new committee to help the European Commission advance in the field of rare disease policy

N/A
N/A
Protected

Academic year: 2021

Partager "The European Union Committee of Experts on Rare Diseases (EUCERD): a new committee to help the European Commission advance in the field of rare disease policy"

Copied!
2
0
0

Texte intégral

(1)

HAL Id: inserm-00663880

https://www.hal.inserm.fr/inserm-00663880

Submitted on 27 Jan 2012

HAL is a multi-disciplinary open access

archive for the deposit and dissemination of

sci-entific research documents, whether they are

pub-lished or not. The documents may come from

teaching and research institutions in France or

abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est

destinée au dépôt et à la diffusion de documents

scientifiques de niveau recherche, publiés ou non,

émanant des établissements d’enseignement et de

recherche français ou étrangers, des laboratoires

publics ou privés.

The European Union Committee of Experts on Rare

Diseases (EUCERD): a new committee to help the

European Commission advance in the field of rare

disease policy

Antoni Moliner, Ségolène Aymé

To cite this version:

Antoni Moliner, Ségolène Aymé. The European Union Committee of Experts on Rare Diseases

(EU-CERD): a new committee to help the European Commission advance in the field of rare disease

pol-icy. 5th European Conference on Rare Diseases (ECRD 2010), May 2010, Krakow, Poland. pp.O28,

�10.1186/1750-1172-5-S1-O28�. �inserm-00663880�

(2)

ORAL PRESENTATION

Open Access

The European Union Committee of Experts on

Rare Diseases (EUCERD): a new committee to

help the European Commission advance in the

field of rare disease policy

Antoni Montserrat Moliner

1*

, Ségolène Aymé

2

From 5th European Conference on Rare Diseases (ECRD 2010)

Krakow, Poland. 13-15 May 2010

The European Union Committee of Experts on Rare Diseases was formally established via the European Commission decision of 30 November 2009 (2009/ 872/EC). The EUCERD will aid the European Com-mission (EC) with the preparation and implementation of Community activities in the field of rare diseases, in cooperation and consultation with the specialised bodies in Member States, the relevant European authorities in the fields of research and public health action and other relevant stakeholders acting in the field. The EUCERD replaces the EC’s Rare Diseases Task Force. Members of the EUCERD include repre-sentatives of: each Member State, patient organisa-tions, the pharmaceutical industry, ongoing/past Community projects in the field of RD, ongoing/past RD projects financed by Community Framework Pro-grammes for Research and Technological Develop-ment, DG Sanco, DG Research, DG Enterprise, Eurostat, and the ECDC. The EUCERD will foster exchanges of relevant experience, policies and prac-tices between these parties and is charged with the following responsibilities: assisting the EC in the mon-itoring, evaluating and disseminating the results of measures taken at Community and national level in the field of rare diseases; contributing to the imple-mentation and improvement of Community actions in the field; contributing to the preparation of EC reports on the implementation of the Commission Communi-cation and the Council Recommendation; delivering

opinions, recommendations or submitting reports to the EC either at the latter’s request or on its own initiative; assisting the EC in international cooperation on matters relating to rare diseases; assisting the EC in drawing up guidelines, recommendations and any other action defined in the Commission Communica-tion and in the Council RecommendaCommunica-tion; providing an annual report of its activities to the EC. The EUCERD may establish temporary Working Groups including external experts for specific missions.

The Scientific Secretariat of the EUCERD is supported by an EC Joint Action.

Author details

1

European Commission: Health and Consumers General-Directorate (SANCO), Luxembourg.2Leader of the former Rare Disease Task Force (INSERM SC11

Orphanet), Paris, France.

Published: 19 October 2010

doi:10.1186/1750-1172-5-S1-O28

Cite this article as: Moliner and Aymé: The European Union Committee of Experts on Rare Diseases (EUCERD): a new committee to help the European Commission advance in the field of rare disease policy. Orphanet Journal of Rare Diseases 2010 5(Suppl 1):O28.

*Correspondence: Antoni.Montserrat@ec.europa.eu

1

European Commission: Health and Consumers General-Directorate (SANCO), Luxembourg

Full list of author information is available at the end of the article

Moliner and Aymé Orphanet Journal of Rare Diseases 2010, 5(Suppl 1):O28 http://www.ojrd.com/content/5/S1/O28

Références

Documents relatifs

Using data from the 1999–2004 legislature, I test the hypothesis that there is some degree of specialization in the actual assignment process for the two largest political groups,

However, the right to an effective judicial remedy is also, next to its recognition under Article 47 CFR recognised as General Principle of EU law (Article 6(3) TEU), the

Afin d’agrandir son offre en Suisse romande et toucher les clients romands, la fondation, disposant de peu de moyens financiers, pourrait être soutenue par les sections romandes de

Output-oriented average scores suggest that countries of the sample can improve their performance in PISA mean score and early leavers output by 6%, their average number of

Keywords: Rare diseases, Health information exchange, Patient identification systems, Identity federation, Patient data

Promising in vitro – in vivo correlations with human skin does, however, show some promise as surrogate approaches for systemic absorption and it is reasonable to assume that

Academic research continues to document that corporate insiders earn abnormal profits on trade in corporate stock, and at the same time, capital market regulators

An example of another very interesting class of irrelevant dependencies is shown in Figure 9, where the dependency for package a can always be satisfied despite the conflict